Human Reproduction, Vol. 16, No. 2, 319-325,
February 2001
© 2001 European Society of Human Reproduction and Embryology
HMG is as good as recombinant human FSH in terms of oocyte and embryo quality: a prospective randomized trial
Department of Obstetrics & Gynaecology, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China
Previous studies have demonstrated that the use of recombinant human follicle stimulating hormone (rhFSH) for ovarian stimulation may be associated with a better outcome than human menopausal gonadotrophin (HMG), probably due to the absence of LH, higher FSH bioactivity and better quality of oocytes and embryos when rhFSH is used. Very few studies have examined the effects of different gonadotrophins on oocyte and embryo quality. In this prospective study, 40 women undergoing ovarian stimulation for intracytoplasmic sperm injection were randomized to receive a standard protocol of either HMG or rhFSH in down-regulated cycles. Prior to microinjection, each denuded oocyte was videotaped to assess nuclear maturity, morphology of zona pellucida, oocyte and polar body and the zona thickness, and diameters of oocyte and ooplasma. Fertilization and subsequent embryo development of each oocyte were followed. The embryologists were blind to the type of gonadotrophin each patient had received for stimulation. No significant differences were found between the two groups with regard to the demographic data, the ovarian responses and pregnancy/implantation rates. The percentage of metaphase II oocytes in the HMG and rhFSH groups were similar (86.9 versus 87.4% respectively). All other parameters assessing oocyte and embryo quality were also comparable between the two groups.
Key words: HMG/ICSI/oocyte and embryo quality/ovarian stimulation/recombinant human FSH
1 To whom correspondence should be addressed at: Department of Obstetrics and Gynaecology, 6/F, Professorial Block,Queen Mary Hospital, Pokfulam Road, Hong Kong. E-mail: nghye{at}hkucc.hku.hk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Bosch, C. Vidal, E. Labarta, C. Simon, J. Remohi, and A. Pellicer Highly purified hMG versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists--a randomized study Hum. Reprod., October 1, 2008; 23(10): 2346 - 2351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-L. Lee, Y. Liu, P.-Y. Ng, K.-F. Lee, C.-L. Au, E. H.-Y. Ng, P.-C. Ho, and W. S.-B. Yeung Aberrant expression of angiopoietins-1 and -2 and vascular endothelial growth factor-A in peri-implantation endometrium after gonadotrophin stimulation Hum. Reprod., April 1, 2008; 23(4): 894 - 903. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Coomarasamy, M. Afnan, D. Cheema, F. van der Veen, P. M.M. Bossuyt, and M. van Wely Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis Hum. Reprod., February 1, 2008; 23(2): 310 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. W. Chan, E. H. Y. Ng, O. S. Tang, W. S. B. Yeung, E. Y. L. Lau, and P. C. Ho A Prospective, Randomized, Double-Blind Study to Compare Two Doses of Recombinant Human Chorionic Gonadotropin in Inducing Final Oocyte Maturity and the Hormonal Profile during the Luteal Phase J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 3933 - 3938. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-J. Huang, K.-C. Lan, F.-T. Kung, M.-Y. Tsai, C.-Y. Chang, H.-W. Huang, Y.-C. Lin, and S.-Y. Chang Human cumulus-free oocyte maturational profile and in vitro developmental potential after stimulation with recombinant versus urinary FSH Hum. Reprod., February 1, 2004; 19(2): 306 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Y.-P. Ho, J.-L. Hwang, M.-J. Chen, H.-F. Guu, and E. S.-C. Ho What is the LH ceiling level for follicular growth arrest in late follicular phase? Hum. Reprod., February 1, 2004; 19(2): 463 - 464. [Full Text] [PDF]
|
|
|
|
|
|
Z. Kilani, A. Dakkak, S. Ghunaim, G.E. Cognigni, C. Tabarelli, L. Parmegiani, and M. Filicori A prospective, randomized, controlled trial comparing highly purified hMG with recombinant FSH in women undergoing ICSI: ovarian response and clinical outcomes Hum. Reprod., June 1, 2003; 18(6): 1194 - 1199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Filicori, G. E. Cognigni, and W. Ciampaglia Effects of LH on oocyte yield and developmental competence Hum. Reprod., June 1, 2003; 18(6): 1357 - 1358. [Full Text] [PDF]
|
|
|
|
|
|
J. Tesarik Effects of LH on oocyte yield and developmental competence Hum. Reprod., June 1, 2003; 18(6): 1358 - 1360. [Full Text] [PDF]
|
|
|
|
|
|
N. Gleicher, M. Vietzke, and A. Vidali Bye-bye urinary gonadotrophins?: Recombinant FSH: A real progress in ovulation induction and IVF? Hum. Reprod., March 1, 2003; 18(3): 476 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Al-Inany, M. Aboulghar, R. Mansour, and G. Serour Meta-analysis of recombinant versus urinary-derived FSH: an update Hum. Reprod., February 1, 2003; 18(2): 305 - 313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.J. Dyer Bye-bye urinary gonadotrophins?: The conflict between effective and affordable health care--a perspective from the developing world Hum. Reprod., July 1, 2002; 17(7): 1680 - 1683. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Al-Inany and M. Afnan Models of cost-effectiveness of recombinant FSH versus urinary FSH. Hum. Reprod., June 1, 2002; 17(6): 1671 - 1673. [Full Text] [PDF]
|
|
|
|
|
|
J. H. Check HMG is possibly superior to recombinant FSH for IVF Hum. Reprod., November 1, 2001; 16(11): 2473 - 2473. [Full Text] [PDF]
|
|